Core Viewpoint - PRF Technologies Ltd. has undergone a corporate name change from PainReform to reflect its evolution into a diversified innovation platform, expanding beyond its original single-product focus into specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics [1][2]. Company Evolution - The name change signifies a strategic shift as the company broadens its portfolio across multiple high-growth markets, continuing to advance its non-opioid postoperative pain therapy PRF-110 while establishing additional growth platforms through LayerBio and DeepSolar [3][4]. Pharmaceutical Platform Expansion - PRF has entered the ophthalmology market with OcuRing™-K, a patented sustained-release ocular therapy aimed at addressing pain and inflammation post-cataract surgery, a multi-billion-dollar global market [4][5]. - OcuRing™-K is designed for controlled, localized therapy from a single application, eliminating the need for weeks of post-surgical eye drops, and is advancing toward the next stage of clinical development [5]. AI-Driven Energy Analytics - The company has developed DeepSolar, an AI-driven solar analytics and digital asset-management business targeting the expanding global renewable-energy market, transforming complex data into actionable intelligence for solar assets [6]. - DeepSolar has moved from development to early commercial deployment, with pilot projects progressing into customer engagements as solar assets age [6]. Strategic Growth Positioning - The transition to PRF Technologies Ltd. aims to build long-term value through diversification, platform scalability, and disciplined execution across healthcare and clean-energy technology markets [7]. - The company is focused on creating multiple platforms and paths forward, reducing reliance on any single outcome to establish durable, long-term value [8]. Company Overview - PRF Technologies Ltd. is a diversified innovation company advancing specialty pharmaceutical therapies and AI-driven energy analytics, focusing on improving patient outcomes while reducing reliance on opioids [9].

Core Insights - PainReform Ltd. has announced positive safety data from Phase I human studies and preclinical evaluations of its OcuRing™-K platform, which supports its advancement toward Investigational New Drug (IND) submission [1][6] Group 1: Safety and Efficacy - The development program included preclinical rabbit studies and a Phase I clinical study in patients undergoing cataract surgery, demonstrating a favorable safety profile for the OcuRing™-K platform [2] - In the Phase I clinical study, no treatment-emergent adverse events related to the study drug were observed, and all reported adverse events were consistent with cataract surgery expectations [3] - Preclinical studies showed favorable local tolerability with no ocular tissue abnormalities, supporting consistent safety findings across both preclinical and clinical evaluations [4] Group 2: Product Features and Development - OcuRing™-K is designed for targeted, sustained release of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids through a single intraoperative application, utilizing a preservative-free formulation [5] - The company is advancing IND-enabling activities, with preparations underway to support the next phase of clinical evaluation in the United States [6] Group 3: Company Overview - PainReform Ltd. focuses on reformulating established therapeutics for post-operative pain management and aims to improve patient outcomes while reducing reliance on opioids [7]

Core Insights - PainReform Ltd. has launched Smart TDD, an advanced solar Technical Due Diligence service aimed at providing comprehensive assessments of solar asset performance and risk, enhancing audit capabilities for various stakeholders in the solar industry [1][4] Industry Overview - The solar industry is experiencing unprecedented growth, with over $500 billion invested in 2024 and more than $60 billion in solar assets changing hands annually, creating a significant demand for reliable technical assessments as many assets reach warranty expiration or show underperformance [2][4] Company Developments - Smart TDD addresses the limitations of traditional TDD processes by offering complete data coverage, advanced diagnostics, actionable outputs, and fast turnaround times, thus supporting all major checkpoints in a solar plant's lifecycle [3][7] - The launch of Smart TDD positions DeepSolar as a trusted analytics partner in the global solar sector, responding to the increasing demand for high-quality technical due diligence services amid rising performance issues and M&A activity [4][7] Technological Advancements - Smart TDD combines AI-driven analytics with physics-based modeling and expert engineering reviews to provide a full-picture audit, enabling investors and owners to better understand the assets they are acquiring, operating, or insuring [3][7] - The service promises to deliver preliminary results within days of data upload, significantly reducing deal friction and enhancing decision-making for buyers and financiers [7]

Core Insights - PainReform Ltd. has completed an R&D assessment of LayerBio's drop-less, sustained-release ocular drug-delivery platform, confirming its potential to reduce or eliminate reliance on medicated eye drops for cataract patients [1][4] - The platform has successfully incorporated corticosteroids and NSAIDs, indicating its technical feasibility for multi-drug delivery [2] - The OcuRing, a pre-fabricated device, allows for sustained-release drug delivery during cataract surgery, improving patient comfort and compliance, particularly among elderly patients [3] Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform, reflecting a strategic commitment to healthcare and sustainable energy [5] - The company's pharmaceutical programs utilize a proprietary extended-release drug-delivery system aimed at providing prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids [5]

Core Viewpoint - PainReform Ltd. has initiated a development plan for OcuRing™-K, a patented sustained-release ocular therapy aimed at improving postoperative care in cataract surgery, targeting a significant market opportunity in the multi-billion-dollar global cataract surgery market [1][5]. Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform, reflecting a strategic commitment to applying precision technology across healthcare and sustainable energy sectors [10]. Product Development - OcuRing-K is designed as an erodible, intraoperatively administered device that provides sustained-release of ketorolac, addressing the limitations of traditional eye-drop regimens that often deliver less than 5% of the drug to the target site [2][3]. - The development plan for OcuRing-K includes progressing towards a Phase II clinical trial, with a focus on post-cataract pain and inflammation as the initial target indication [1][7]. Clinical and Market Context - Cataract surgery is a prevalent procedure, with approximately 4.5 million surgeries performed annually in the U.S. and a global surgical procedure volume exceeding $9 billion [5]. - Current postoperative management relies heavily on multi-week corticosteroid and NSAID eye-drop regimens, which are burdensome for elderly patients and often inconsistently delivered [5]. Technological Advantages - OcuRing-K's in-situ depot formulation allows for direct, localized delivery to target tissues, providing controlled and stable therapeutic coverage while reducing systemic exposure and contamination risks associated with traditional drops [3][4]. - Preclinical studies and Phase I evaluations have shown that OcuRing-K can reduce post-surgical pain and inflammation with lower total drug exposure compared to standard regimens, enhancing patient compliance [4]. Future Plans - PainReform and LayerBio plan to advance OcuRing-K through its next stage of clinical development in the U.S., which could unlock a high-volume reimbursable market and enable expansion into additional ophthalmic indications [7].

Core Insights - PainReform Ltd. has announced advancements in its solar energy business unit, DeepSolar, focusing on the development of an automated reporting engine that enhances solar asset performance analysis and communication [1][3]. Company Overview - PainReform Ltd. operates in two main sectors: reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform [5]. - DeepSolar specializes in advanced digital asset management technologies for utility-scale solar plants, utilizing AI algorithms to convert complex operational data into actionable insights [4][5]. Product Development - The new AI-powered reporting engine aims to automate the process of generating performance reports, which currently requires manual data aggregation from various systems [2][3]. - This engine will consolidate and interpret data from multiple sources, providing customized reports in minutes, tailored to user-defined analysis depth, visualization style, and reporting frequency [3]. Strategic Vision - The automated reporting system is seen as a significant step towards making DeepSolar's AI capabilities more practical and accessible, facilitating a quicker transition from analysis to actionable insights [4].

Core Insights - PainReform Ltd.'s solar energy business unit, DeepSolar, is gaining attention for its AI-driven solar analytics, particularly through its participation in the NVIDIA Connect program [1][2] - DeepSolar Predict, an AI-based forecasting module, aims to enhance energy production forecasts and operational decision-making for solar asset managers [2][4] - The increasing operational complexity in utility-scale solar necessitates advanced data interpretation and management strategies to maintain profitability in a volatile market [3] Company Overview - DeepSolar develops advanced digital asset management technologies specifically for utility-scale solar plants, utilizing AI algorithms to transform operational data into actionable insights [6] - The company is focused on commercial deployment and is progressing towards its first pilot projects with prospective customers, indicating potential long-term value creation [5][6] - PainReform Ltd. operates with a dual business model, combining pharmaceutical programs with AI-driven energy optimization technologies through DeepSolar, reflecting a strategic commitment to high-impact sectors [7]

Financial Performance - The company reported a net loss of $2,316,000 for the six months ended June 30, 2025, a significant reduction compared to a loss of $12,818,000 for the same period in 2024, indicating an improvement of approximately 82%[4] - The Company reported a total operating loss of $2,368,000 for the six months ended June 30, 2025, with the clinical development segment contributing a loss of $1,687,000 and the solar segment contributing a loss of $681,000[55] - The Company reported a loss before taxes on income of $2,316,000 for the reporting period[55] Assets and Liabilities - As of June 30, 2025, total assets increased to $11,162,000 from $4,525,000 as of December 31, 2024, representing a growth of 146%[3] - The accumulated deficit increased to $58,767,000 as of June 30, 2025, compared to $56,451,000 as of December 31, 2024, showing an increase of 4%[3] - Cash and cash equivalents decreased to $3,479,000 as of June 30, 2025, down from $4,261,000 at the end of 2024, reflecting a decline of 18%[3] - The total accrued expenses as of June 30, 2025, were $1,831,000, slightly down from $1,904,000 as of December 31, 2024, indicating a decrease of approximately 3.8%[25] Capital and Financing - The company raised $1,338,000 from the issuance of shares, warrants, and prefunded warrants during the six months ended June 30, 2025[9] - Management plans to continue capital raising through the sale of additional equity securities and strategic partnerships to fund operations[16] - Between June 30, 2025, and the date of issuance of the financial statements, the Company raised approximately $2.7 million by issuing 1,062,199 ordinary shares under its At-the-Market offering program[58] - The company generated gross proceeds of approximately $1.34 million from the issuance of 362,960 ordinary shares through an At-the-Market (ATM) offering between January 1, 2025, and June 30, 2025[28] Acquisitions and Investments - The company completed an asset acquisition of AI-driven solar analytics technology, DeepSolar, in March 2025, enhancing its technology portfolio[11] - In August 2025, the company acquired a majority equity interest in LayerBio, Inc., which is advancing sustained-release drug delivery technologies in ophthalmology[12] - The Company has entered into a Preferred Stock Purchase Agreement to acquire 51% of LayerBio for $600, with potential additional investment of up to $2.4 million contingent on specific milestones[58] - The company completed an asset acquisition of Bladeranger Ltd. for a total consideration valued at $7,292,000, which included the issuance of various warrants and shares[44] - The fair value of the acquired intangible asset from the acquisition was determined using a discounted cash flow approach, resulting in a net carrying amount of $7,119,000 after accumulated amortization of $173,000[45] Operational Insights - The company expects to continue incurring losses until its products reach commercial profitability, with no assurance of achieving this[15] - As of June 30, 2025, no revenue was recognized in either the clinical development or the solar segment[54] - Consulting expenses for the clinical development segment totaled $740,000, while the solar segment incurred $285,000 in consulting expenses[55] Shareholder and Management Actions - The company approved an increase in its authorized share capital by an additional 7,500,000 ordinary shares, pending shareholder approval[29] - As of June 30, 2025, the company had 220,320 options outstanding under the 2019 Share Option Plan, with a weighted average exercise price of $10.26[33] - The company’s management does not expect the ongoing military conflict in Israel to have a material impact on its operations or business results[23] - The company’s lease agreement for its principal offices was extended until July 31, 2026, with an annual rent reduction of approximately $12,000[26] - The Company extended its lease agreement for its principal offices in Tel Aviv, Israel, to July 2026, with monthly rent of $5, linked to the CPI, and total lease expenses of $30,000 in 2025[50] - The weighted average remaining lease term for the Company's office space is 1 year, with a discount rate of 8.5%[50] Financial Income - For the six months ended June 30, 2025, the total financial income, net was $52,000, a decrease of 43.5% compared to $92,000 for the same period in 2024[52] - The company recognized share-based compensation expenses of $389,000 for the year ended June 30, 2025, compared to $146,000 for the year ended June 30, 2024, reflecting an increase of 166%[36]

Core Insights - PainReform Ltd. has made significant advancements in both specialty pharmaceuticals and renewable energy technologies during the first half of 2025, focusing on non-opioid solutions for pain management and AI-driven solar analytics [3][12] Pharmaceutical Programs - The company acquired a majority interest in LayerBio, enhancing its pipeline with the OcuRing™-K platform, a novel therapy targeting a global market of approximately $9 billion for post-surgical pain management [6][7] - Continued development of PRF-110 is underway, which showed significant efficacy in the early postoperative period despite not meeting primary endpoints in a Phase 3 trial [7] DeepSolar Division - The DeepSolar division has shown strong momentum, highlighted by the completion of the MyDeepSolar consumer app and acceptance into NVIDIA's Connect Program, which will aid in developing the DeepSolar Predict forecasting solution [3][14] - A successful 92MW pilot project with Econergy in Romania has transitioned into the company's first commercial customer agreement, marking a significant step in commercial deployment [3][14] Financial Performance - The company reduced its net loss to approximately $2.3 million for the six months ended June 30, 2025, down from $12.8 million in the same period the previous year [11] - Research and development expenses significantly decreased to approximately $0.3 million compared to $11.4 million in the prior year, primarily due to the completion of the Phase 3 clinical trial for PRF-110 [9] - As of June 30, 2025, PainReform maintained cash and cash equivalents of approximately $3.5 million and positive working capital of approximately $1.5 million [11]

Core Insights - Shares of PainReform surged nearly 130% after its renewable energy arm, DeepSolar, was accepted into the Nvidia Connect Program, trading at $3.06, although the stock is still down over 20% year-to-date [1] Group 1: Nvidia Partnership and Technology - Through the Nvidia program, DeepSolar will access advanced AI frameworks and tools to enhance its solar forecasting solution, DeepSolar Predict, which aims to improve weather forecast accuracy by up to 50% [2] - The integration of NVIDIA's AI capabilities with DeepSolar's expertise is expected to redefine photovoltaic energy forecasting and optimization [3] Group 2: Financial Performance and Challenges - Despite the recent stock surge, PainReform shares have lost over 80% in the past year, indicating ongoing struggles for the company [4] - The company is diversifying into biotechnology with a majority stake acquisition in LayerBio, which supports the development of OcuRing-K, a drug delivery system for post-surgical pain management [4][5] - The investment in OcuRing-K could total $3 million, with $600,000 already committed [5]